摘要
目的:评价基因芯片技术在乙型肝炎(乙肝)基因分型和拉米夫定耐药性检测中的临床价值。方法:选择287例乙肝病毒 (HBV)免疫学标志物阳性患者,用PCR法筛选HBV-DNA阳性血清,用肝炎基因诊断芯片进行基因分型,并对拉米夫定治疗中YM- DD基因变异进行分析。结果:153例HBV-DNA阳性者中,B基因型8例,C基因型144例,B/C混合型1例;拉米夫定治疗1年以 上、3个月-1年、少于3个月的YMDD突变率分别为41.46％、16.00％和3.20％。结论:肝炎基因芯片可用于乙肝诊断分型,并可 对拉米夫定治疗后耐药性进行判断。
Objective:To evaluate the clinical role of DNA microarray in detection of HBV genotpes and Lamivudine drug resistance test. Methods:HBV-DNA positive surum was selected by PCR from 287 cases with positive immunological markers for HBV. Then DNA microarray of hepatitis B virus was applied to detect HBV genotypes and to analyze YMDD genovariation in Lamivdine treatment. Results:Of all 153 cases with positive HBV-DNA,8 B genotypes, 144 C genotypes and 1 B/C genotypes were found respectively; YMDD genocariation rate on different course of Lamivudine treatment, over one year, three months to one year and shorter than three months, were 41.66% , 16.00% and 3.20% ,respectively. Conclusions:Hepatitis DNA microarray was applicable to diagnosis of hepatitis B virus genotypes and to judgment of drug resistance after Lamivudine treatment.
出处
《华北国防医药》
2005年第1期6-7,共2页
Medical Journal of Beijing Military Region
